Frank Chambers
Director, Inhalytic
Inhalytic Ltd is an analytical chemistry testing consultancy set up by Frank Chambers (Formerly of AstraZeneca and Mylan) in July 2018 specialising in the analysis of Orally Inhaled and Nasal Drug Products (OINDP’s). Inhalytic has formed a strategic link with the Medway Centre for Pharmaceutical Sciences, which is affiliated to the Faculty of Science and Engineering at The University of Greenwich at Medway. This allows Inhalytic to provide laboratory support and consultancy services to the pharmaceutical industry over a wide range of analytical techniques used to characterise, develop and performance test OINDP’s.
I am a member of the EPAG Impactor sub-team, and I have published a number of posters and scientific abstracts at international conferences such as RDD and DDL.
Primary Services
• Inhaled Pharmaceutical testing
• Analyst Training
• Spacer performance evaluation
• Impactor testing (including Abbreviated Impactor Measurement – AIM)
• pMDI platform development analysis
• Data Interpretation
• Analytical Trouble shooting
• In Vivo In Vitro testing (IVIVC)
– Oropharyngeal cast testing
– Breathing simulation studies
• Introduction of new test equipment, test procedures and competencies into Analytical Testing Laboratories
– Plume Geometry
– Spacer testing methods
– Shake and fire Characterisation equipment for pMDI
• CRO/CMO selection and oversight
